← Назад

Progressive supranuclear palsy

ORPHA:683DiseaseNot applicableAdult, Elderly

Фенотипы (32)

Очень частый (80–99%)9
HP:0000605Supranuclear gaze palsy
HP:0000623Supranuclear ophthalmoplegia
HP:0002015Dysphagia
HP:0002172Postural instability
HP:0002317Unsteady gait
HP:0002527Falls
HP:0002529Neuronal loss in central nervous system
HP:0012535Abnormal synaptic transmission
HP:0100710Impulsivity
Частый (30–79%)19
HP:0000505Visual impairment
HP:0000511Vertical supranuclear gaze palsy
HP:0000514Slow saccadic eye movements
HP:0000643Blepharospasm
HP:0000712Emotional lability
HP:0000716Depression
HP:0000737Irritability
HP:0000741Apathy
HP:0000750Delayed speech and language development
HP:0001260Dysarthria
HP:0001332Dystonia
HP:0002067Bradykinesia
HP:0002120Cerebral cortical atrophy
HP:0002171Gliosis
HP:0002200Pseudobulbar signs
HP:0002321Vertigo
HP:0002354Memory impairment
HP:0002381Aphasia
HP:0100543Cognitive impairment
Периодический (5–29%)4
HP:0000496Abnormality of eye movement
HP:0000726Dementia
HP:0001337Tremor
HP:0002063Rigidity

Эпидемиология (10)

Annual incidence
1-9 / 100 000
Worldwide
Point prevalence
1-9 / 100 000
Worldwide
Point prevalence
1-5 / 10 000
Europe
Point prevalence
1-9 / 100 000
United States
Point prevalence
1-9 / 100 000
Italy
Point prevalence
1-5 / 10 000
Guadeloupe
Point prevalence
1-9 / 100 000
United Kingdom
Annual incidence
1-9 / 1 000 000
Libyan Arab Jamahiriya
Annual incidence
1-9 / 1 000 000
United States
Annual incidence
1-9 / 1 000 000
Australia

Лекарства и терапия

Источник: Open Targets Platform (в реальном времени)

Клинические исследования

Источник: ClinicalTrials.gov (в реальном времени)

Внешние ресурсы